The Carlyle Group reports today with the stock down 10% over the past month — and a long string of analyst target reductions telling much of the story.
The positioning picture, on its own, is not alarming. Short interest is 4.7% of free float, up about 13% over the past month but still a moderate level. Borrowing costs remain near-trivial at 0.56%, despite rising roughly 40% over the past week. Borrow availability is ample at 614% — more than six shares available to borrow for every one already lent out — leaving no meaningful squeeze dynamics at play. Options positioning has shifted modestly more defensive. The put/call ratio is at 1.02, modestly above its 20-day average of 0.80, though the z-score of roughly 1.0 keeps it well within normal bounds. The lending market and derivatives desk, in short, are cautious but not charged.
The real story ahead of this print is how far the analyst community has moved against the stock. TD Cowen downgraded Carlyle to Hold from Buy on May 8 and then lowered its target again just ten days later, now at $50. JPMorgan and Barclays both trimmed targets the same day. Goldman Sachs cut its target from $81 to $69 in early April. Morgan Stanley moved from $71 to $66. The direction of travel is uniform: the consensus mean target is $60.50, a 36% premium to Tuesday's close of $44.49 — yet nearly every firm that has moved recently has moved lower. That gap between target and price reflects a Street that still sees a recovery case but has been methodically marking it down. The bull thesis rests on Carlyle's $474 billion AUM platform and the depth of its global credit book at $208 billion. Bears point to deployment uncertainty and flagging carry realizations weighing on near-term fee-related earnings.
The ownership picture adds context. The three co-founders — Daniel D'Aniello, David Rubenstein and William Conway — still hold a combined 24% of shares outstanding, tying the company's long-term trajectory tightly to management alignment. However, Rubenstein sold 500,000 shares at $46.68 in March and CEO Harvey Schwartz sold 134,000 shares in February when the stock was above $54. The broader insider ledger over the past 90 days shows net selling of roughly $85.6 million — a consistent flow of stock off the insider base at prices well above where the stock trades today. Harris Associates added 1.4 million shares in Q1 and Capital Research added 821,000, providing a partial institutional counterweight.
Past prints have not generated outsized moves: the May 2026 report produced just a 0.3% one-day decline, and the prior quarter ended with a 0.2% drop on the day. The quiet historical reaction pattern means that today's print is less a volatility event and more a test of whether Carlyle can deliver fee-related earnings and fundraising momentum that gives analysts reason to stop cutting — or a data point that accelerates the downgrades.
See the live data behind this article on ORTEX.
Open CG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
